World Journal of Urology

, Volume 32, Issue 4, pp 959–964 | Cite as

Application of the 2013 American Urological Association early detection of prostate cancer guideline: Who will we miss?

Original Article

Abstract

Purpose

The American Urological Association (AUA) published new prostate cancer (CaP) screening guidelines in 2013. We apply the guidelines to a retrospective cohort to compare tumor characteristics of those no longer recommended for screening with those who remain screening candidates.

Methods

We identified cases of screening detected CaP (stage cT1c) in the Surveillance Epidemiology and End Results database from October 2005 to December 2010. The 2013 AUA Guidelines were retrospectively applied to the cohort. Men were categorized into three groups for comparison based on whether or not they would now be recommended for CaP screening (Unscreened, Young Unscreened, and Screened). We compared clinical and pathological characteristics of CaP across study groups.

Results

A total of 142,382 men were identified. Screening would no longer be recommended for 40,160. Those no longer recommended for screening had higher median PSA (6.4 vs. 5.8 ng/mL, p < 0.01), more Gleason 7 and ≥8 CaP on prostate biopsy (36.4 vs. 34.8 %, p < 0.001; 12.4 vs. 9.2 %, p < 0.001, respectively) and slightly more Gleason ≥8 CaP (9.0 vs. 7.5 %, p = 0.03), and T3 tumors (17.3 vs. 16.5 %, p = 0.01) at prostatectomy. Nodal and distant metastasis rates were clinically equivalent among men screened and unscreened. Subgroup analysis of young patients (40–54 years old) no longer recommended for screening identified intermediate or high-risk Gleason scores at prostatectomy 57.6 % of the time.

Conclusions

Features of CaP in men no longer recommended for routine screening are largely equivalent to if not worse than those in screened men.

Keywords

Prostate cancer Screening Guidelines Prostate-specific antigen 

Notes

Acknowledgments

Special thanks to Mr. John Cashy for assistance with statistical analysis and data acquisition.

Conflict of interest

The authors certify that there is no actual or potential conflict of interest in relation to this article.

Ethical standards

All patient data in this study were acquired through the fully de-identified SEER database, which is collected and disseminated via the National Cancer Institute in a manner compliant with the 1964 Declaration of Helsinki and later amendments.

References

  1. 1.
    Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324(17):1156–1161. doi: 10.1056/NEJM199104253241702 PubMedCrossRefGoogle Scholar
  2. 2.
    Moyer VA (2012) Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 157(2):120–134. doi: 10.7326/0003-4819-157-2-201207170-00459 PubMedCrossRefGoogle Scholar
  3. 3.
    Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. doi: 10.1056/NEJMoa0810084 PubMedCrossRefGoogle Scholar
  4. 4.
    Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319. doi: 10.1056/NEJMoa0810696 PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, Chevrette E, Levesque J (2004) Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59(3):311–318. doi: 10.1002/pros.20017 PubMedCrossRefGoogle Scholar
  6. 6.
    Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P (2011) Randomised prostate cancer screening trial: 20 year follow-up. BMJ 342:d1539. doi: 10.1136/bmj.d1539 PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O (2009) 15-Year followup of a population based prostate cancer screening study. J Urol 181(4):1615–1621; discussion 1621. doi: 10.1016/j.juro.2008.11.115
  8. 8.
    Catalona WJ, D’Amico AV, Fitzgibbons WF, Kosoko-Lasaki O, Leslie SW, Lynch HT, Moul JW, Rendell MS, Walsh PC (2012) What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med 157(2):137–138. doi: 10.7326/0003-4819-157-2-201207170-00463 PubMedCrossRefGoogle Scholar
  9. 9.
    AUA Response to USPSTF PSA Recommendations (2011)Google Scholar
  10. 10.
    AACU Rejects USPSTF Recommendations (2012) http://aacuweb.org/pdf/AACU_PSA_Statement_05-22-12.pdf. Accessed 12 Aug 2013
  11. 11.
    Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL (2013) Early detection of prostate cancer: AUA guideline. J Urol 190(2):419–426. doi: 10.1016/j.juro.2013.04.119 PubMedCrossRefGoogle Scholar
  12. 12.
    Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P (2009) Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232–2241. doi: 10.1016/j.juro.2009.07.093 PubMedCrossRefGoogle Scholar
  13. 13.
    Carter HB (2013) American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int 112(5):543–547. doi: 10.1111/bju.12318 PubMedCrossRefGoogle Scholar
  14. 14.
    Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973–2010) (released April 2013, based on the November 2012 submission.). National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, http://www.seer.cancer.gov
  15. 15.
    Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29(9):1228–1242Google Scholar
  16. 16.
    Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC (1990) Family history and the risk of prostate cancer. Prostate 17(4):337–347PubMedCrossRefGoogle Scholar
  17. 17.
    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):215–224. doi: 10.1056/NEJMoa030660 PubMedCrossRefGoogle Scholar
  18. 18.
    Cohn JA, Wang CE, Lakeman JC, Silverstein JC, Brendler CB, Novakovic KR, McGuire MS, Helfand BT (2014) Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Urol Oncol 32 (1):41 e23–e30. doi: 10.1016/j.urolonc.2013.04.013
  19. 19.
    Aslani A, Minnillo BJ, Johnson B, Cherullo EE, Ponsky LE, Abouassaly R (2013) The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol. doi: 10.1016/j.juro.2013.12.010 PubMedGoogle Scholar
  20. 20.
    Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71(11):3582–3593PubMedCrossRefGoogle Scholar
  21. 21.
    Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Adami HO, Johansson JE (2008) Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100(16):1144–1154. doi: 10.1093/jnci/djn255 PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185(3):869–875. doi: 10.1016/j.juro.2010.10.057 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111(5):753–760. doi: 10.1111/j.1464-410X.2012.11611.x PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124–137. doi: 10.1016/j.eururo.2013.09.046 PubMedCrossRefGoogle Scholar
  25. 25.
    Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ (2013) The Melbourne consensus statement on the early detection of prostate cancer. BJU Int. doi: 10.1111/bju.12556 Google Scholar
  26. 26.
    Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH (2012) Baseline prostate-specific antigen testing at a young age. Eur Urol 61(1):1–7. doi: 10.1016/j.eururo.2011.07.067 PubMedCrossRefGoogle Scholar
  27. 27.
    Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Bjork T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H (2013) Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40–55 and long term risk of metastasis: case–control study. BMJ 346:f2023. doi: 10.1136/bmj.f2023 PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    van den Bergh RC, Essink-Bot ML, Roobol MJ, Schroder FH, Bangma CH, Steyerberg EW (2010) Do anxiety and distress increase during active surveillance for low risk prostate cancer? J Urol 183(5):1786–1791. doi: 10.1016/j.juro.2009.12.099 PubMedCrossRefGoogle Scholar
  29. 29.
    Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdottir U, Fall K (2010) Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst 102(5):307–314. doi: 10.1093/jnci/djp537 PubMedCrossRefGoogle Scholar
  30. 30.
    Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ (2006) Characteristics of patients with familial versus sporadic prostate cancer. J Urol 176(6 Pt 1):2438–2442; discussion 2442. doi: 10.1016/j.juro.2006.07.159

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of UrologyNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations